Nevertheless, a meta-analysis of 22 trials that investigated the efficacy of another immune checkpoint inhibitor targeting the co-inhibitory PD1-PDL1 dyad in patients with lung cancer demonstrated that atherosclerotic cardiovascular disease occurred in 3% of the patients [33]. Here, CD274 is linked to lung carcinoma.